The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study.
 
Yoichiro Hamamoto
No Relationships to Disclose
 
Yoshihito Kogure
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD; Taiho Pharmaceutical
Research Funding - MSD (Inst)
 
Akiko Kada
No Relationships to Disclose
 
Hiroya Hashimoto
No Relationships to Disclose
 
Shinji Atagi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hideo Saka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD K.K; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Noriyuki Ebi
No Relationships to Disclose
 
Akira Inoue
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mundipharma; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Shionogi
Consulting or Advisory Role - AstraZeneca; Lilly Japan; MSD
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Shionogi (Inst)
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Takeharu Yamanaka
Honoraria - AstraZeneca; Bayer; Chugai Pharma; Pfizer; Taiho Oncology; Takeda
Research Funding - Astellas Pharma; Bayer; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
Travel, Accommodations, Expenses - ESMO
 
Masahiko Ando
Consulting or Advisory Role - Asahi Kasei
Research Funding - Kyowa Kirin (Inst)
 
Shunichiro Iwasawa
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED.; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Kaoru Kubota
Speakers' Bureau - Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim; Ono Pharmaceutical
 
Mitsuhiro Takenoyama
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Covidien; Johnson & Johnson; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); KM Biologics (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Seto
Employment - Precision Medicine Asia
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Covidien; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kissei Pharmaceutical (Inst); Lilly Japan (Inst); Loxo (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Life Technologies; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyorin (Inst); Lilly (Inst); Maruho (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Toppan Printing Co. (Inst); Tosoh Corporation (Inst); Tsumura & Co. (Inst)
 
Akihiko Gemma
Consulting or Advisory Role - Nihonkayaku
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical